Phase 2 study of cobicistat versus ritonavir each with once-daily atazanavir and fixed-dose emtricitabine/tenofovir df in the initial treatment of HIV infection
Richard Elion(Gilead Sciences (United States)), David R. Warren(Gilead Sciences (United States)), Trevor Hawkins(University of Florida), Anita Mathias(Gilead Sciences (United States)), Peter Shalit(Research Triangle Park Foundation), Steven L. Chuck(Gilead Sciences (United States)), Calvin Cohen(Community Research Initiative), Brian P. Kearney(Belfast Health and Social Care Trust), Joseph Gathe, Hui C. Liu(Gilead Sciences (United States))
Cited by 92
Related Papers
Tenofovir DF, Emtricitabine, and Efavirenz vs. Zidovudine, Lamivudine, and Efavirenz for HIV
|New England Journal of Medicine|2006|886
Long-term Therapy With Adefovir Dipivoxil for HBeAg-Negative Chronic Hepatitis B for up to 5 Years
|Gastroenterology|2006|882
Infections with<i>Cryptococcus neoformans</i>in the Acquired Immunodeficiency Syndrome
|New England Journal of Medicine|1989|801
All‐oral 12‐week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY‐3 phase III study
|Hepatology|2015|689
The Cost Effectiveness of Combination Antiretroviral Therapy for HIV Disease
|New England Journal of Medicine|2001|519